Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
- Status
- RECRUITING
- Phase
- PHASE2
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- Status
- RECRUITING
- Phase
- PHASE2
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE2
GITMO AML/MDS-Relapse Registry Study
- Status
- COMPLETED
- Phase
- N/A
Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
- Status
- RECRUITING
- Phase
- NA
Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions
- Status
- RECRUITING
- Phase
- NA
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- Status
- RECRUITING
- Phase
- PHASE1
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
- Status
- RECRUITING
- Phase
- N/A
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
- Status
- SUSPENDED
- Phase
- PHASE1
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Status
- RECRUITING
- Phase
- PHASE1
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
- Status
- RECRUITING
- Phase
- PHASE2